Compare iShares MSCI Indonesia ETF (EIDO) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Tilray Brands Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.19, while Tilray Brands Inc trades at $4.34 (market cap $541.36M). The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | TLRY | |
|---|---|---|
52-Week High | $19.22 | $21.00 |
52-Week Low | $10.80 | $4.31 |
Market Cap | — | $541.36M |
Sector | — | Health |
Enterprise Value | — | $638.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.205, up 1.12% on the day, while technical indicators signal a bearish trend with moving averages and an overbought short-term RSI. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal plan and central bank rate hikes to support the currency. However, key financial ratios for the underlying fund holdings are unavailable in the provided data.
The outlook is mixed, balancing Indonesia's long-term GDP growth potential from government programs against near-term risks from currency volatility and geopolitical pressures. The ETF's dividend yield remains a draw, but a reported 27% dividend cut in 2025 signals underlying economic challenges for income-focused investors.
TLRY trades at $4.36, down 0.57% on the day, amid a bearish technical signal and mixed quarterly earnings. The company reported a net loss of -$2.19 billion for 2025 despite revenue growth to $821 million, with a negative net income margin of -156.67%. Recent developments include medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.
While low valuation ratios (P/S of 0.55, P/B of 0.35) suggest potential undervaluation, persistent losses and negative cash flow from operations pose significant risks. Analyst sentiment is cautious with a 'Hold' consensus, reflecting concerns over profitability despite growth initiatives. The stock's outlook hinges on achieving sustainable profitability and navigating competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
